Smartleaf Asset Management
CORT icon

Smartleaf Asset Management’s Corcept Therapeutics CORT Stock Holding History

Smartleaf Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$249K Buy
2,166
+1,560
+257% +$168K 0.01% 836
2026
Q2 		$53.3K Hold
606
– – ﹤0.01% 1480
2026
Q1 		$23.1K Sell
606
-1,643
-73% -$61.4K ﹤0.01% 1866
2025
Q4 		$158K Buy
2,249
+224
+11% +$17.6K 0.01% 928
2025
Q3 		$170K Buy
2,025
+252
+14% +$18.2K 0.01% 793
2025
Q2 		$130K Sell
1,773
-415
-19% -$30.1K 0.01% 764
2025
Q1 		$120K Sell
2,188
-183
-8% -$11.1K 0.01% 762
2024
Q4 		$121K Buy
2,371
+1,795
+312% +$94.1K 0.01% 760
2024
Q3 		$25.3K Buy
576
+229
+66% +$8.14K ﹤0.01% 1223
2024
Q2 		$11.1K Buy
+347
New +$9.5K ﹤0.01% 1352

Other funds holding CORT

Parallel Advisors
Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Smartleaf Asset Management's CORT Position: Q3 2026 in Review

Smartleaf Asset Management increased its Corcept Therapeutics (CORT) stake by 257% in Q3 2026, buying an estimated $168K and bringing the position to 2,166 shares worth $249K. The position accounts for 0.01% of the portfolio, ranked #836.

Smartleaf Asset Management first reported a position in CORT in Q2 2024 and has held it in 10 quarters since. 262 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Smartleaf Asset Management held 2,166 shares of Corcept Therapeutics worth $249K as of Q3 2026.
  • Smartleaf Asset Management bought 1,560 Corcept Therapeutics shares in Q3 2026, an estimated $168K.
  • Corcept Therapeutics made up 0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #836 holding.
  • Smartleaf Asset Management first reported a position in Corcept Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • 262 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.